February 9, 2015 | The Israeli company developing drug delivery platforms, SteadyMed Therapeutics filed with the US Securities and Exchange Commission to raise $55 million in a NASDAQ IPO. The company made the move just ten days after raising $12.2 million in equity financing. The reported underwriters for the IPO are Wells Fargo, RBC and JP Morgan. SteadyMed was founded as part of the RAD Biomed incubator. The company is headquartered in San Ramon, California, but a good deal of product development still occurs in Rehovot, Israel. SteadyMed was founded in 2005 and has developed the PatchPump for drug delivery and other novel drug delivery methods.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments